Literature DB >> 27553470

Gallium-68 EDTA PET/CT for Renal Imaging.

Michael S Hofman1, Rodney J Hicks2.   

Abstract

Nuclear medicine renal imaging provides important functional data to assist in the diagnosis and management of patients with a variety of renal disorders. Physiologically stable metal chelates like ethylenediaminetetraacetic acid (EDTA) and diethylenetriamine penta-acetate (DTPA) are excreted by glomerular filtration and have been radiolabelled with a variety of isotopes for imaging glomerular filtration and quantitative assessment of glomerular filtration rate. Gallium-68 ((68)Ga) EDTA PET usage predates Technetium-99m ((99m)Tc) renal imaging, but virtually disappeared with the widespread adoption of gamma camera technology that was not optimal for imaging positron decay. There is now a reemergence of interest in (68)Ga owing to the greater availability of PET technology and use of (68)Ga to label other radiotracers. (68)Ga EDTA can be used a substitute for (99m)Tc DTPA for wide variety of clinical indications. A key advantage of PET for renal imaging over conventional scintigraphy is 3-dimensional dynamic imaging, which is particularly helpful in patients with complex anatomy in whom planar imaging may be nondiagnostic or difficult to interpret owing to overlying structures containing radioactive urine that cannot be differentiated. Other advantages include accurate and absolute (rather than relative) camera-based quantification, superior spatial and temporal resolution and integrated multislice CT providing anatomical correlation. Furthermore, the (68)Ga generator enables on-demand production at low cost, with no additional patient radiation exposure compared with conventional scintigraphy. Over the past decade, we have employed (68)Ga EDTA PET/CT primarily to answer difficult clinical questions in patients in whom other modalities have failed, particularly when it was envisaged that dynamic 3D imaging would be of assistance. We have also used it as a substitute for (99m)Tc DTPA if unavailable owing to supply issues, and have additionally examined the role of (68)Ga EDTA PET/CT for measuring glomerular filtration rate and split renal function.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27553470     DOI: 10.1053/j.semnuclmed.2016.04.002

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  9 in total

1.  Radiolabeled polyoxometalate clusters: Kidney dysfunction evaluation and tumor diagnosis by positron emission tomography imaging.

Authors:  Dalong Ni; Dawei Jiang; Hyung-Jun Im; Hector F Valdovinos; Bo Yu; Shreya Goel; Todd E Barnhart; Peng Huang; Weibo Cai
Journal:  Biomaterials       Date:  2018-04-12       Impact factor: 12.479

2.  The use of 68Ga-EDTA PET allows detecting progressive decline of renal function in rats.

Authors:  Andrea O Fontana; Mary Gonzalez Melo; Gilles Allenbach; Costa Georgantas; Ruijia Wang; Olivier Braissant; Frederic Barbey; John O Prior; Diana Ballhausen; David Viertl
Journal:  Am J Nucl Med Mol Imaging       Date:  2021-12-15

3.  Assessing Glomerular Filtration in Small Animals Using [68Ga]DTPA and [68Ga]EDTA with PET Imaging.

Authors:  Daniel Gündel; Ulrike Pohle; Erik Prell; Andreas Odparlik; Oliver Thews
Journal:  Mol Imaging Biol       Date:  2018-06       Impact factor: 3.488

4.  Crystal structure of aqua-(2-{[2-({2-[bis-(carboxyl-ato-κO-meth-yl)amino-κN]eth-yl}(carboxyl-ato-κO-meth-yl)amino-κN)eth-yl](carb-oxy-meth-yl)aza-niumyl}acetato)-gallium(III) trihydrate.

Authors:  Martin Wallin; Peter Turner; Andrew Katsifis; Mingshi Yang; Hak-Kim Chan
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2018-07-06

Review 5.  The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?

Authors:  Rudolf A Werner; Alexander Weich; Malte Kircher; Lilja B Solnes; Mehrbod S Javadi; Takahiro Higuchi; Andreas K Buck; Martin G Pomper; Steven P Rowe; Constantin Lapa
Journal:  Theranostics       Date:  2018-11-29       Impact factor: 11.556

6.  The next era of renal radionuclide imaging: novel PET radiotracers.

Authors:  Rudolf A Werner; Xinyu Chen; Constantin Lapa; Kazuhiro Koshino; Steven P Rowe; Martin G Pomper; Mehrbod S Javadi; Takahiro Higuchi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-30       Impact factor: 9.236

7.  First experiences with dynamic renal [68Ga]Ga-DOTA PET/CT: a comparison to renal scintigraphy and compartmental modelling to non-invasively estimate the glomerular filtration rate.

Authors:  David Kersting; Miriam Sraieb; Robert Seifert; Pedro Fragoso Costa; Sandra Kazek; Lukas Kessler; Lale Umutlu; Wolfgang Peter Fendler; Walter Jentzen; Ken Herrmann; Florian Büther; Michael Nader; Christoph Rischpler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-04-12       Impact factor: 10.057

8.  11C-PABA as a PET Radiotracer for Functional Renal Imaging: Preclinical and First-in-Human Study.

Authors:  Camilo A Ruiz-Bedoya; Alvaro A Ordonez; Rudolf A Werner; Donika Plyku; Mariah H Klunk; Jeff Leal; Wojciech G Lesniak; Daniel P Holt; Robert F Dannals; Takahiro Higuchi; Steven P Rowe; Sanjay K Jain
Journal:  J Nucl Med       Date:  2020-03-20       Impact factor: 11.082

Review 9.  18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging.

Authors:  Rudolf A Werner; Thorsten Derlin; Constantin Lapa; Sara Sheikbahaei; Takahiro Higuchi; Frederik L Giesel; Spencer Behr; Alexander Drzezga; Hiroyuki Kimura; Andreas K Buck; Frank M Bengel; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.